keyword
MENU ▼
Read by QxMD icon Read
search

Psychosis in parkinson

keyword
https://www.readbyqxmd.com/read/29132271/capgras-syndrome-in-advanced-parkinson-s-disease
#1
Christopher L Groth, Antonia Pusso, Scott A Sperling, Diane S Huss, W Jeffrey Elias, G Frederick Wooten, Matthew J Barrett
Psychosis is common in Parkinson's disease (PD), especially in advanced disease, and can lead to a number of psychotic symptoms, including delusions. One uncommon delusion is Capgras syndrome (CS). The authors report on three PD patients with a history of deep brain stimulation (DBS) who developed this delusion. The anatomic targets in these three patients were the subthalamic nuclei in two patients and the globus pallidus interna in one patient. The length of time between surgery and development of CS varied but was greater than 6 months...
November 14, 2017: Journal of Neuropsychiatry and Clinical Neurosciences
https://www.readbyqxmd.com/read/29120562/be-vigilant-for-dementia-in-parkinson%C3%A2-s-disease
#2
Flavia Niccolini, Konstantinos Diamantopoulos, Stelios Kiosses, Marios Politis
It is estimated that up to 80% of patients with Parkinson's disease will eventually develop cognitive impairment over the course of their illness. Even at the time of diagnosis, cognitive impairment has been reported in 20-25% of patients. Commonly affected cognitive domains are executive function, visuospatial ability and attention control. In addition, patients with Parkinson's disease dementia may present with deficits in language function and verbal memory. Psychosis may occur in approximately 40% of patients with Parkinson's disease, and is associated with an increased risk of developing cognitive impairment...
May 2017: Practitioner
https://www.readbyqxmd.com/read/29105858/investigation-of-metabolic-profile-of-pimavanserin-in-rats-by-uhplc-combined-with-fourier-transform-ion-cyclotron-resonance-mass-spectrometry
#3
Wenying Wu, Yanjie Chu, Shixiao Wang, Xiaoyang Sun, Jingjing Zhang, Yannian Wang, Xiaohui Chen
RATIONALE: Pimavanserin, a selective serotonin 2A receptor inverse agonist, is a promising candidate for treating Parkinson's disease psychosis. Our previous study exhibited that there might be an existence of extensive metabolites of pimavanserin in rats. However, the metabolic fate of pimavanserin in vivo remains unknown. Thus, it is essential to develop an efficient method to investigate metabolic profile of pimavanserin in rats. Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR-MS) to date has the highest mass measurement accuracy and resolution of any mass spectrometry platforms...
November 6, 2017: Rapid Communications in Mass Spectrometry: RCM
https://www.readbyqxmd.com/read/29104810/management-of-psychosis-in-parkinson-s-disease-emphasizing-clinical-subtypes-and-pathophysiological-mechanisms-of-the-condition
#4
REVIEW
Raquel N Taddei, Seyda Cankaya, Sandeep Dhaliwal, K Ray Chaudhuri
Investigation into neuropsychiatric symptoms in Parkinson's disease (PD) is sparse and current drug development is mainly focused on the motor aspect of PD. The tight association of psychosis with an impaired quality of life in PD, together with an important underreporting of this comorbid condition, contributes to its actual insufficient assessment and management. Furthermore, the withdrawal from access to readily available treatment interventions is unacceptable and has an impact on PD prognosis. Despite its impact, to date no standardized guidelines to the adequate management of PD psychosis are available and they are therefore highly needed...
2017: Parkinson's Disease
https://www.readbyqxmd.com/read/29101795/impaired-frontal-lobe-functions-in-patients-with-parkinson-s-disease-and-psychosis
#5
Naveen Thota, Abhishek Lenka, Lija George, Shantala Hegde, Shyam Sundar Arumugham, Shweta Prasad, Albert Stezin, Nitish Kamble, Ravi Yadav, Pramod Kumar Pal
INTRODUCTION: Patients with Parkinson's disease (PD) may develop several non-motor symptoms (NMS). Psychosis is one of the debilitating NMS of PD. The neurobiology of psychosis is not fully understood. This study aims to compare the frontal lobe functions of PD patients with and without psychosis using the Frontal Assessment Battery (FAB). METHODOLOGY: This study included 69 patients with PD; 34 with psychosis (PD-P) and 35 without psychosis (PD-NP). Mini Mental Status Examination (MMSE) was used to screen for cognitive impairment...
October 28, 2017: Asian Journal of Psychiatry
https://www.readbyqxmd.com/read/29098976/pimavanserin-for-the-treatment-of-parkinson-s-disease-psychosis-number-needed-to-treat-number-needed-to-harm-and-likelihood-to-be-helped-or-harmed
#6
Leslie Citrome, James C Norton, Kathy Chi-Burris, George Demos
OBJECTIVE: Our aim was to describe the efficacy and tolerability of pimavanserin, a highly selective serotonin 5-HT2A receptor inverse agonist/antagonist indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP), using the metrics of number needed to treat (NNT) and number needed to harm (NNH). METHODS: Categorical efficacy and tolerability data were extracted from the clinical trial databases of the double-blind placebo-controlled studies of pimavanserin in persons with PDP...
November 3, 2017: CNS Spectrums
https://www.readbyqxmd.com/read/29093347/comparative-utility-of-atypical-antipsychotics-for-the-treatment-of-psychosis-in-parkinson-s-disease-a-systematic-review-and-bayesian-network-meta-analysis
#7
Ryo Iketani, Yohei Kawasaki, Hiroshi Yamada
We performed a systematic review and Bayesian network meta-analysis to determine atypical antipsychotics that are effective and safe for the treatment of psychosis in Parkinson's disease (PD). We conducted a comprehensive literature search using PubMed/MEDLINE, Cochrane Library, and Japana Centra Revuo Medicina (Ichu-shi Web). We used randomized controlled trials evaluating the utility of atypical antipsychotics for the treatment of psychosis in PD using the Brief Psychiatric Rating Scale (BPRS) and the Unified PD rating Scale parts III (UPDRS-III) as the endpoints...
2017: Biological & Pharmaceutical Bulletin
https://www.readbyqxmd.com/read/29073741/a-systematic-review-of-the-effectiveness-of-medical-cannabis-for-psychiatric-movement-and-neurodegenerative-disorders
#8
REVIEW
Keane Lim, Yuen Mei See, Jimmy Lee
The discovery of endocannabinoid's role within the central nervous system and its potential therapeutic benefits have brought forth rising interest in the use of cannabis for medical purposes. The present review aimed to synthesize and evaluate the available evidences on the efficacy of cannabis and its derivatives for psychiatric, neurodegenerative and movement disorders. A systematic search of randomized controlled trials of cannabis and its derivatives were conducted via databases (PubMed, Embase and the Cochrane Central Register of Controlled Trials)...
November 30, 2017: Clinical Psychopharmacology and Neuroscience: the Official Scientific Journal of the Korean College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/29064136/pyridoxamine-a-novel-treatment-for-schizophrenia-with-enhanced-carbonyl-stress
#9
Masanari Itokawa, Mitsuhiro Miyashita, Makoto Arai, Takashi Dan, Katsuyoshi Takahashi, Taro Tokunaga, Kayo Ishimoto, Kazuya Toriumi, Tomoe Ichikawa, Yasue Horiuchi, Akiko Kobori, Satoshi Usami, Takeo Yoshikawa, Naoji Amano, Shinsuke Washizuka, Yuji Okazaki, Toshio Miyata
AIM: The aim of this clinical trial was to obtain proof of concept for high-dose pyridoxamine as a novel treatment for schizophrenia with enhanced carbonyl stress. METHODS: Ten Japanese schizophrenia patients with high plasma pentosidine, which is a representative biomarker of enhanced carbonyl stress, were recruited in a 24 week, open trial in which high-dose pyridoxamine (ranging from 1200 to 2400 mg/day) was administered using a conventional anti-psychotic regimen...
October 24, 2017: Psychiatry and Clinical Neurosciences
https://www.readbyqxmd.com/read/29059136/successful-use-of-escitalopram-for-the-treatment-of-visual-hallucinations-in-patients-with-parkinson-disease
#10
Joseph Bergman, Paul P Lerner, Shmuel Sokolik, Vladimir Lerner, Anatoly Kreinin, Chanoch Miodownik
INTRODUCTION: Patients with Parkinson disease (PD) frequently experience visual hallucinations (VH). Visual hallucinations are most often viewed as an adverse effect of antiparkinsonian treatment. Possible treatments for this disturbance include a reduction of antiparkinsonian medications, adding atypical antipsychotics, or cholinesterase inhibitors. Some studies demonstrated that selective serotonin reuptake inhibitors may be an optional treatment for patients experiencing psychosis or agitation in dementia...
November 2017: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/29047301/pimavanserin-novel-pharmacotherapy-for-parkinson-s-disease-psychosis
#11
Zeyad T Sahli, Frank I Tarazi
Pimavanserin is the first FDA-approved atypical antipsychotic drug indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Areas covered: This review focuses on the preclinical discovery of pimavanserin. It analyzes the pharmacological, behavioral and molecular mechanisms of pimavanserin and their contribution to the therapeutic advantages of the drug as reported in published preclinical and clinical studies, and product labels. Expert opinion: Pimavanserin exhibits a unique pharmacological profile with nanomolar affinity at serotonin 5-HT2A and 5-HT2C receptors...
October 19, 2017: Expert Opinion on Drug Discovery
https://www.readbyqxmd.com/read/29018160/dopamine-dysregulation-syndrome-in-parkinson-s-disease-a-systematic-review-of-published-cases
#12
Nicola Warren, Cullen O'Gorman, Alexander Lehn, Dan Siskind
OBJECTIVES: Dopamine dysregulation syndrome (DDS) is an uncommon complication of the treatment of Parkinson's disease, characterised by addictive behaviour and excessive use of dopaminergic medication. DDS may frequently go unrecognised or misdiagnosed. We aimed to clarify current understanding of presentation, risk factors, comorbidities and management of DDS. METHODS: Case reports were identified through a systematic search of databases (PubMed, Embase) with the following terms: dopaminergic dysregulation syndrome, hedonistic homeostatic dysregulation, dopamine/levodopa addiction...
October 10, 2017: Journal of Neurology, Neurosurgery, and Psychiatry
https://www.readbyqxmd.com/read/28990131/diagnosis-and-management-of-cognitive-and-behavioral-changes-in-dementia-with-lewy-bodies
#13
REVIEW
Babak Tousi
Proper diagnosis of dementia with Lewy bodies (DLB) in clinical practice remains suboptimal as many cases are misdiagnosed, usually as Alzheimer disease (AD) or Parkinson's disease (PD) and, in rare cases, psychosis. Therefore, it is important for patients with dementia to be thoroughly evaluated by a specialist who is familiar with current diagnostic tests and treatment options. New diagnostic criteria from the Dementia with Lewy Bodies Consortium have been developed to increase diagnostic sensitivity for DLB (Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium; McKeith et al...
October 9, 2017: Current Treatment Options in Neurology
https://www.readbyqxmd.com/read/28952832/prevalence-and-pattern-of-antipsychotic-induced-movement-disorders-in-a-tertiary-care-teaching-hospital-in-india-a-cross-sectional-study
#14
Nimisha Desai, Parvati B Patel, Sandip Shah, Tejas K Patel, Saurabh N Shah, Ela Vatsala
OBJECTIVES: To assess prevalence and pattern of movement disorders among patients taking antipsychotic medications. METHODS: This cross-sectional, intensive monitoring (patient interview, case record form review and clinical examination) study was conducted in patients taking antipsychotic drugs irrespective of duration for the development of movement disorders. The psychiatrist used Modified Simpson-Angus Scale score (10-item scale), Barnes' rating scale and Abnormal Involuntary Movement Scale to diagnose parkinsonism, akathisia and tardive dyskinesia, respectively...
September 27, 2017: International Journal of Psychiatry in Clinical Practice
https://www.readbyqxmd.com/read/28944257/affective-correlates-of-psychosis-in-parkinson-s-disease
#15
Stewart A Factor, Michael K Scullin, Alan Freeman, Donald L Bliwise, William M McDonald, Felicia C Goldstein
OBJECTIVE: To examine the nature of the association between affective disorders and psychosis in Parkinson's disease (PD). BACKGROUND: In PD, psychosis and affective disorders are common and independently impact quality of life and mortality. Both depression and psychosis are correlated with the occurrence of cognitive dysfunction, suggesting that they may share neurobiological substrates. Anxiety has not been examined as a correlate of psychosis. METHODS: 144 PD subjects were evaluated with the Schedule for Assessment of Positive Symptoms to assess psychotic features, while depression and anxiety were examined by the Structured Clinical Interview for DSM-IV-TR (SCID) and self-assessment scales Beck Depression Inventory II (BDI-II) and Beck Anxiety Inventory (BAI)...
March 2017: Movement Disorders Clinical Practice
https://www.readbyqxmd.com/read/28928050/predictors-of-onset-of-psychosis-in-patients-with-parkinson-s-disease-who-gets-it-early
#16
Abhishek Lenka, Lija George, Shyam Sundar Arumugham, Shantala Hegde, Venkateswara Reddy, Nitish Kamble, Ravi Yadav, Pramod Kumar Pal
INTRODUCTION: Psychosis is one of the common non-motor symptoms of PD, which substantially worsens the quality of life. Hence, it is important to identify factors that are associated with early onset of psychosis in PD. In order to identify those factors, the current study aims to compare various demographic and clinical features of PD patients with early and late onset psychosis. METHODOLOGY: In this prospective case-control study, 51 consecutive patients with PD having psychosis (PDP) were recruited...
September 14, 2017: Parkinsonism & related Disorders
https://www.readbyqxmd.com/read/28890132/motor-abnormalities-in-first-episode-psychosis-patients-and-long-term-psychosocial-functioning
#17
Manuel J Cuesta, Elena García de Jalón, M Sol Campos, Lucía Moreno-Izco, Ruth Lorente-Omeñaca, Ana M Sánchez-Torres, Víctor Peralta
Motor abnormalities (MAs) are highly prevalent in patients with first-episode psychosis both before any exposure and after treatment with antipsychotic drugs. However, the extent to which these abnormalities have predictive value for long-term psychosocial functioning is unknown. One hundred antipsychotic-naive first-episode psychosis (FEP) patients underwent extensive motor evaluation including catatonic, parkinsonism, dyskinesia, akathisia and neurological soft signs. Patients were assessed at naïve state and 6months later...
September 7, 2017: Schizophrenia Research
https://www.readbyqxmd.com/read/28880354/-pimavanserin-a-new-treatment-for-the-parkinson-s-disease-psychosis
#18
J H Duits, M S Ongering, H J M Martens, P F J Schulte
Clozapine is an effective drug for treating psychosis in Parkinson's disease (PDP) and is registered as such in the Netherlands. However, clozapine can have adverse effects, including agranulocytosis. The new drug pimavanserin was recently registered in the United States for the treatment of PDP.<br/> AIM: To review the literature on pimavanserin and discuss the position it currently occupies in the Netherlands as a potential treatment for PDP.<br/> METHOD: Systematic search of the literature.<br/> RESULTS: We found reports on four randomised controlled trials (RCTs), one review and six articles about the pharmacokinetics and pharmacodynamics of pimavanserin...
2017: Tijdschrift Voor Psychiatrie
https://www.readbyqxmd.com/read/28856542/imaging-behavioural-complications-of-parkinson-s-disease
#19
Mikaeel Valli, Alexander Mihaescu, Antonio P Strafella
In addition to motor symptoms, behavioural complications are commonly found in patients with Parkinson's disease (PD). Behavioural complications, including depression, anxiety, apathy, impulse control disorder and psychosis, together have a large impact on PD patient's quality of life. Many neuroimaging studies using PET, SPECT and MRI techniques have been conducted to study the underlying neural mechanisms of PD pathogenesis and pathophysiology in relation to its behavioural complications. This review will survey these PET, SPECT and MRI studies to describe the current understanding of the neuro-chemical, functional and structural changes associated with behavioural complications in PD patients...
August 30, 2017: Brain Imaging and Behavior
https://www.readbyqxmd.com/read/28834102/ventral-striatal-dopaminergic-defect-is-associated-with-hallucinations-in-parkinson-s-disease
#20
E Jaakkola, J Joutsa, E Mäkinen, J Johansson, V Kaasinen
BACKGROUND AND PURPOSE: Visual hallucinations (VHs) are a common complication of Parkinson's disease (PD). The pathogenesis of VHs in PD is still largely unclear. The aim of this study was to investigate the dopaminergic mechanisms of VHs and specifically whether the degree of striatal dopamine transporter (DAT) function or extrastriatal serotonin transporter (SERT) function can predict the appearance of VHs in patients with PD. METHODS: Twenty-two PD patients scanned with [(123) I]FP-CIT single photon emission computed tomography at an early stage of their disease who later developed VHs were identified and compared with 48 non-hallucinating PD patients...
November 2017: European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies
keyword
keyword
69147
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"